Quite bullish trading statement - Proteome Sciences has agreed a non-exclusive license agreement with Oncimmune Ltd for the use of its Annexin 1 and Annexin 2 autoantibody patents for the fields of diagnosis and for monitoring treatment in lung cancer. The terms of the license agreement were not disclosed.
2008 has been a transformational year for the Company and it looks forward with confidence to further realising its potential in 2009.
According to the update, Proteome Sciences continues to make strong progress in other disease applications and is in advanced negotiations to out-license further candidates in its biomarker portfolio in both stroke and Alzheimer's disease and also from ProteoSHOP® services activities.
I don't know much about this company - anyone have any background?
http://www.stockopedia.com/news/announcement/PRM/090106prm8bab.htm
